FDA-APPROVED PRODUCT THERAPY AREAS

FDA-approved Product

Therapy Areas

Sanofi’s rare blood disorder franchise is focused on hemophilia A and B with or without inhibitors and acquired thrombotic thrombocytopenic purpura (aTTP).

Educational Resources

Hemophilia

Trends in the Hemophilia Treatment Landscape
An overview of the history of hemophilia care, currently approved therapies, the comprehensive patient care model and introduction to products currently in the hemophilia therapy pipeline.

Acquired Thrombotic Thrombocytopenic Purpura

ISTH Guidelines for TTP 2021
A presentation summarizing guidelines established by the International Society on Thrombosis and Haemostasis (ISTH) for the diagnosis and treatment of thrombotic thrombocytopenic purpura (TPP), including the use of caplacizumab in patients with aTTP. The presentation also describes the methodologies used to develop the guidelines.

ISTH Guidelines on TTP